Placebo Response Can Hide a Pain Signal: What Sponsors Can Change Before First Patient In
In pain clinical trials, a study that fails to separate from placebo does not always provide a clear answer about whether a therapy works.
For small and mid-sized biotechs, this can create a difficult question: did the therapy fail to demonstrate efficacy, or did aspects of study design and execution make the efficacy signal harder to detect?
Placebo response is one part of a broader challenge around assay sensitivity, particularly in early proof-of-concept pain trials where development decisions can depend heavily on the interpretability of the data.
Reducing uncertainty before enrolment begins
Our latest report explores the factors that can influence assay sensitivity before the first patient is enrolled, and where sponsors can take practical steps to reduce avoidable variability.
It considers key areas including:
- Patient selection and eligibility criteria
- Baseline qualification and symptom stability
- Background and rescue medication
- Endpoint selection and consistent execution
- Site and investigator readiness
- Monitoring strategies that identify variability early
Rather than viewing placebo response as a single statistical issue, the report considers assay sensitivity as both a clinical development and operational challenge.
The objective is not to eliminate every source of variability. It is to understand which factors are most likely to compromise the study’s ability to answer its primary efficacy question, and address those risks while there is still an opportunity to influence them.
Planning pain clinical trials with interpretability in mind
For biotech teams preparing an early-phase pain clinical trial, decisions made during protocol development, site selection, training and study start-up can have a significant impact on the quality and interpretability of the eventual data.
This report provides a practical framework for reviewing those decisions before first patient in, helping development teams consider where avoidable uncertainty may enter the trial and how it can be managed.
Download the full report to explore the considerations that can help strengthen assay sensitivity in pain clinical trials.